Literature DB >> 11468013

Biotransformation in vitro of the 22R and 22S epimers of budesonide by human liver, bronchus, colonic mucosa and skin.

J Cortijo1, E Urbieta, R Bort, J V Castell, C Ruiz-Bravo, J Martinez, R Palacios-Pelaez, S Lledó, E J Morcillo.   

Abstract

The pharmacological effects of glucocorticoids are greatly influenced by their pharmacokinetic properties. In the present report, the in vitro biotransformation of the 22R and 22S epimers of the topical steroid budesonide was studied in the S-9 fraction of human liver, bronchus, skin and colonic mucosa. The disappearance of unchanged epimers of budesonide was measured during 90 min of incubation by high performance liquid chromatography. The rate of disappearance was high in human liver while little biotransformation occurred in bronchial tissue and colonic mucosa, and none was detected in the skin. A marked decay of the initial concentration of unchanged budesonide epimers was noticed after 2 h incubation in cultured human hepatocytes, while only a small decrease was observed after 24 h incubation in cultured human airway smooth muscle cells and BEAS-2B cells. The 22R epimer of budesonide suffered greater in vitro biotransformation than the 22S epimer in human hepatic, bronchial and colonic tissues. These findings extend those of other studies, and confirm that the high therapeutic ratio of budesonide is due to negligible local biotransformation combined with high level of liver metabolism for locally absorbed budesonide.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468013     DOI: 10.1046/j.1472-8206.2001.00005.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  2 in total

Review 1.  Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.

Authors:  Staffan Edsbäcker; Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Identification and Quantification by NMR Spectroscopy of the 22R and 22S Epimers in Budesonide Pharmaceutical Forms.

Authors:  Natalia E Kuz'mina; Sergey V Moiseev; Elena Y Severinova; Evgenii A Stepanov; Natalia D Bunyatyan
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.